Clinical Trial Update: Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens [Phase 2]

View source ↗

Summary

Phase 2 study evaluating trastuzumab deruxtecan monotherapy in HER2-expressing gastric or GEJ adenocarcinoma after two or more prior regimens completed with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: AstraZeneca | Conditions: Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2024-11-21